Skin cancer (all types)
Prepared with OnCo (onco.cc/prep/skin-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
14 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Dermoscopy and biopsy for diagnosis, Breslow thickness, ulceration and sentinel node status in melanoma, BRAF V600 mutation in melanoma, PD-L1 and tumour mutational burden as imperfect immunotherapy markers, Merkel cell polyomavirus status), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (basal cell and squamous cell carcinoma), which of the standard options do you recommend and why?
- 6.Am I a candidate for Cemiplimab, Vismodegib, and what side effects should I expect?
- 7.For my situation (melanoma), which of the standard options do you recommend and why?
- 8.Am I a candidate for Pembrolizumab, Nivolumab, Dabrafenib, and what side effects should I expect?
- 9.For my situation (prevention), which of the standard options do you recommend and why?
- 10.Are there clinical trials I could join, for example of Fianlimab, Lifileucel?
- 11.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 12.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 13.I read that “Non-melanoma skin cancer is missing from most cancer registries, so its true burden is unknown”. How does that affect my plan?
- 14.I read that “Melanoma incidence continues to rise in fair-skinned populations”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: Dermoscopy and biopsy for diagnosis, Breslow thickness, ulceration and sentinel node status in melanoma, BRAF V600 mutation in melanoma, PD-L1 and tumour mutational burden as imperfect immunotherapy markers, Merkel cell polyomavirus status.
Scans and tests linked to this cancer: Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive), Dermoscopy, total-body photography & AI skin analysis.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Prevention: Sun protection, avoiding sunbeds and treating actinic keratoses; regular skin checks for people at high risk, with dermoscopy and AI tools improving lesion triage. (Dermoscopy, total-body photography & AI skin analysis)
- Basal cell and squamous cell carcinoma: Surgical excision or Mohs surgery; topical or photodynamic therapy for superficial lesions; radiotherapy when surgery is unsuitable; hedgehog inhibitors for advanced basal cell carcinoma and cemiplimab or pembrolizumab for advanced squamous cell carcinoma. See the subtype pages. (Cemiplimab, Vismodegib)
- Melanoma: Excision with margins by thickness, sentinel node biopsy, adjuvant PD-1 blockade or BRAF/MEK inhibitors for high-risk disease, and checkpoint immunotherapy or targeted therapy for advanced disease. See the melanoma page. (Pembrolizumab, Nivolumab, Dabrafenib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.